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Abstract 
Mesenchymal stem cells (MSCs) are multi-potent cells that can differentiate into various cell 
types and have been used widely in tissue engineering application. In tissue engineering, a 
scaffold, MSCs and growth factors are used as essential components and their interactions 
have been regarded to be important for regeneration of tissues. A critical problem for MSCs 
in tissue engineering is their low survival ability and functionality. Most MSCs are going to 
be apoptotic after transplantation.  Therefore, increasing MSC survival ability and 
functionalities is the key for potential applications of MSCs. Several approaches have been 
studied to increase MSC tissue forming capacity including application of growth factors, 
overexpression of stem cell regulatory genes and improvement of biomaterials for scaffolds. 
The effects of these approaches on MSCs have been associated with the activation of the 
PI3K/Akt signaling pathway. The pathway plays central regulatory roles in MSC survival, 
proliferation, migration, angiogenesis, cytokine production and differentiation. In this review, 
we summarize and discuss the literatures related to the roles of the PI3K/Akt pathway in the 
functionalities of MSCs and the involvement of the pathway in biomaterials-increased MSC 
functinalities. Biomaterials have been modified in their properties, surface structure and 
loaded with growth factors to increase MSC functionalities. Several studies demonstrated that 
the biomaterials-increased MSC functionalities are mediated by the activation of the 
PI3K/Akt pathway.   
Key words: Mesenchymal stem cells, PI3K/Akt pathway, Survival ability, migration, 
angiogenesis, cytokine production, biomaterials 
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1. Introduction 
Mesenchymal stem cells (MSCs) are multi-potent stem cells with the ability to self-renew 
and differentiate into many types of mature cells (1-5). A recent study showed that MSCs can 
be expanded for more than 50 passages in cell culure (6).  MSCs have a fibroblast-like 
morphology and express stromal markers, including CD73, CD105, CD29, CD44 and CD90, 
but not hematopoietic markers (7, 8). MSCs can develop into many different types of tissues 
such as bone, cartilage, fat, tendon, muscle, marrow stroma, nerve and liver (9, 10). Therefore 
these cells are widely applied in regenerative medicine, for examples, bone tissue engineering 
application, in which MSCs are implanted in a scaffold to regenerate new tissues (1, 2, 11-
13). Growth factors are usually added to the system to strengthen MSC functionality (14, 15). 
Although embryonic stem (ES) cells have a much higher capacity to differentiate into many 
cell types (16-18), there are several advantages to use MSCs rather than ES cells in addition 
to the ethical issues. First, ES cells have the potential to cause cancer such as teratoma, an 
encapsulated tumor with different organs such as hair, eye, teeth, bone, and are much more 
difficult to control in vivo than MSCs (19). Second, MSCs are easier to obtain from the bone 
marrow or other tissues such as adipose tissue and umbilical cord blood. Third, MSCs have 
immuno-modulatory effect to decrease transplantation rejection (20). Except tissue 
engineering application, MSCs have also been used alone for cellular therapy to repair 
damaged tissues (21, 22). Systemically administered MSCs have been demonstrated to be 
able to travel to injured tissues and improve tissue regeneration such as heart, brain, renal and 
skeletal tissues (23-27). Preliminary clinical trials of MSCs for the treatment of myocardial 
ischemia and osteogenesis imperfecta have been performed and showed moderate beneficial 
effects (28-31). The knowledge obtained from extensive studies of MSCs in cellular therapy 
could be applicable for tissue engineering. 
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Although MSCs were discovered from bone marrow (BMSCs), they have also been isolated 
from other tissues, including adipose tissue, umbilical cord blood, placenta, dental pulp and 
pancreatic islets (32-36). All these MSCs have similar molecular markers with positive 
expression of mesenchymal markers (CD90, CD29, CD44 and CD105) and lack of CD34, 
CD45, CD11b and HLA-DR) (36, 37). MSCs from adipose tissue (ASCs) are extensively 
studied to substitute BMSCs with several obvious advantages. First, the adipose tissues are 
easier to obtain than bone marrow. Second, MSCs in adipose tissue are much more abundant 
than that in bone marrow. Third, ASCs have higher ability to proliferate than BMSCs (37).  
A major problem in the application of MSCs is that the differentiation capability of MSCs is 
decreased in the transplanted environment (38). This decrease could be due to the new 
extracellular microenvironment, which is different from the natural environment of MSCs 
and is hostile to these cells. Therefore, most MSCs cannot survive long enough to generate 
terminally differentiated cells after transplantation (38). For example, 90% of MSCs were 
shown to be apoptotic, a programmed cell death, within three days after transplantation into 
heart for cardiomyocyte infarct repair (39, 40). However, cellular therapy using MSCs is still 
effective to a certain extent. The beneficial effects of MSCs are thought to be mediated by 
cytokines produced by MSCs rather than new tissues formed from MSCs (39, 41). This may 
also be the case in tissue engineering. Therefore, there is room to further improve the efficacy 
of MSC-based treatments by increasing the survival ability and functionality of MSCs in the 
transplantation environment.  
 
Many different approaches have been used to stimulate MSC proliferation and differentiation 
and to promote long-term survival and functionalities. These approaches include the delivery 
of bioactive materials or proteins (42),  the over-expression of genes in MSCs such as 
vascular endothelial growth factor (VEGF), Akt, bcl-2 (43-48) and the improvement of 
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biomaterials used for scaffolds (49). Interestingly all above approaches are involved in an 
intracellular signal pathway, phosphoinositide 3-kinase/Protein kinase B (PI3K/Akt).  In this 
review, we will summarize the roles of the PI3K/Akt pathway in the functionalities of MSCs, 
how biomaterials affect MSC functionalities via the activation of the PI3K/Akt pathway and 
discuss possible implications.  
 
2. The PI3K/Akt pathway in MSCs 
2.1 Overview of the PI3K/Akt pathway 
The PI3K/Akt pathway is a survival pathway that regulates cell proliferation, apoptosis, 
differentiation and migration (50). The upstream stimulators of the pathway include various 
growth hormones, cytokines and foreign molecules. The PI3K/Akt pathway has been shown 
to play key roles in the physiology and pathophysiology of many types of cells (51-54). 
Abnormal increase or decrease in the PI3K/Akt pathway activity is associated with many 
diseases such as cancer, diabetes, laminopathy, stroke, and neurodegenerative diseases and 
manipulation of the pathway has been proposed for the treatment of these diseases (50). The 
PI3K/Akt also plays a key role in regulating neuronal function through protein ataxin-1, 
GABA receptor and disruption of the pathway is associated with diseases such as Huntingtin 
disease (55).  
 
The key enzyme of the pathway, PI3K, converts phosphatidylinositol 4,5-biphosphate (PIP2) 
into phosphatidylinositol 3,4,5-triphosphate (PIP3), which binds both Akt and 3-
phosphoinositide-dependent protein kinase 1 (PDK1), allowing PDK1 to phosphorylate Akt 
(54, 56). Class 1A PI3K consists of two subunits: the catalytic subunit p110 and the 
regulatory subunit p85. There are four isoforms of p110: p110-alpha, beta, gamma and sigma 
and three p85 isoforms: p85-alpha, beta and gamma. The primary direct downstream target 
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protein of PI3K is Akt. There are three Akt isoforms: Akt1, Akt2 and Akt3 (57). The 
activation of Akt causes a cascade of responses of downstream targets that regulate cellular 
functions (Fig 1). For example, Akt regulates cell migration via Rac1 and rhoA, increases cell 
survival via bcl-2, enhances angiogenesis via VEGF and increases cell proliferation via the 
activation of mTOR (50, 54). 
 
The activation of the PI3K/Akt pathway in MSCs has been applied in both cellular therapy 
and tissue engineering. In cellular therapy studies, stimulators of the pathway and the 
overexpression of some major components of the pathway have been used to induce the 
repair of infarcted cardiovascular cells and were demonstrated to increase the efficacy of 
MSCs (22, 58, 59). In tissue engineering studies, MSCs have been transplanted together with 
various growth factors, such as VEGF and FGF, to increase the functionality of MSCs (14). 
However, the overexpression of key components of the PI3K/Akt pathway has not been 
applied in tissue engineering and warrants further studies. 
 
2.2 The PI3K/Akt pathway and survival ability of MSCs 
The role of the PI3K/Akt in the survival of MSCs is evidenced by the effects of both 
overexpression of key components of this pathway and chemical stimulation of the pathway 
(Fig 2). Mangi et al overexpressed Akt1 in MSCs to improve MSC survival after 
transplantation into the heart in rats (58). The overexpression of Akt1 greatly improved the 
ability of MSCs to treat myocardial infarction. In Akt-overexpressing MSCs, the levels of 
target proteins downstream of Akt, such as anti-apoptotic protein bcl-2, were increased, 
whereas the level of the pro-apoptotic protein bax was decreased. Lim et al. extended the 
study to a large animal model, showing that Akt-overexpressing MSCs also exhibited 
increased efficacy in porcine myocardial infarction (60).  
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Periostin is a matricellular protein which can bind to integrin to activate the PI3K/Akt 
pathway (61, 62). It has been overexpressed in MSCs to increase the survival of these cells 
(59). In periostin-overexpressing MSCs, the PI3K/Akt pathway was activated, and the 
therapeutic efficiency was increased. Periostin-overexpressing MSCs and the conditioned 
medium from these cells were able to increase the survival of cardiomyocytes under hypoxic 
conditions in a co-culture system.  
 
The overexpression of bcl-2 has been shown to increase MSC survival and increase MSC 
function in the treatment of myocardial infarction (63). In a rat model of myocardial 
infarction established by left anterior descending ligation, MSCs overexpressing bcl-2 were 
injected into damaged rat hearts. These MSCs increased the survival of the transplanted cells 
in vivo. In an in vitro experiment, bcl-2 reduced MSC apoptosis by 32% and increased VEGF 
secretion by 60% under hypoxic conditions (63). The over-expression of bcl-2 in MSCs has 
also been shown to increase their ability to protect neurons (64). These gene-overexpressed 
MSCs may be used in tissue engineering in a scaffold to increase tissue formation. 
 
Pre-treatment of MSCs with PI3K/Akt pathway stimulators has been shown to increase MSC 
survival. Several toll-like receptor stimulators have been used to increase MSC functionality 
in tissue engineering, and the PI3K/Akt pathway has been demonstrated to play a key role. 
Wang et al showed that lipopolysaccharide (LPS), a TLR4 ligand, increased MSC survival. 
The pre-treatment of MSCs with 1 mg/ml of LPS protected MSCs from oxidant stress-
induced apoptosis (65). The activation of the PI3K/Akt pathway was demonstrated by the 
increased phosphorylation of Akt at Ser 473 and phosphorylatopn of NF-kB p65 at Ser 536. 
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The effect of LPS was abolished in TLR4-deleted MSCs, indicating that the LPS/TLR4/PI3K 
pathway played a key role. 
 
Stromal cell-derived factor-1 (SDF-1) has been shown to increase MSC survival by several 
studies (66-68). Liu et al demonstrated that SDF-1 can increase the resistance of MSCs to 
apoptosis induced by H2O2 (39). The pretreatment of MSCs with SDF-1 significantly reduced 
apoptosis by activating the PI3K/Akt pathway. In these cells, the Bcl-1/bax ratio was 
increased, indicating a decreased level of apoptosis induced through the mitochondrial 
pathway. Yin et al showed that addition of 0.5-2 µg/ml of SDF-1 inhibited hypoxia and 
serum deprivation-induced apoptosis of MSCs (66). The effect was abolished by PI3K 
inhibitor wortmannin, indicating the important role of the PI3K/Akt pathway in SDF-1-
increased MSC survival. 
 
2.3 The PI3K/Akt pathway and MSC proliferation 
MSCs must proliferate to be applied successfully in tissue engineering. First, MSCs must be 
enriched in vitro through cell proliferation because MSCs are rare in the bone marrow. MSCs 
only account for 0.001 to 0.01% of all bone marrow cells (5, 22). Second, it could be helpful 
if MSCs proliferated after transplantation. It has been shown that the actual number of MSCs 
that form new tissue is far too small (22). This could be caused by low survival rates and 
proliferation. Evidence showed that less than 3% of MSCs persist 2 weeks after 
transplantation (22, 39). In in vitro cell culture, many growth factors have been used to 
stimulate MSC proliferation such as prostaglandin E2 (PGE2), hepatic growth factor (HGF), 
fibroblast growth factor (FGF), tumor necrosis factor-alpha (TNF-alpha), transforming 
growth factor-beta (TGF-beta), epidermal growth factor (EGF) and insulin (69-71). All these 
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factors are stimulators of the PI3K/Akt pathway, indicating the importance of the activation 
of the pathway in the proliferation of MSCs.  
 
The activation of the PI3K/Akt pathway has been demonstrated to be a mediator of several 
factors that increase MSC proliferation. PGE2 has been shown to increase the proliferation of 
MSCs from human umbilical cord blood (70). PGE2 phosphorylates Akt, which in turn 
phosphorylates GSK-3beta, leading to the accumulation of active beta-catenin in the nucleus 
(Fig 3). Beta-catenin is a transcriptional factor that increases the expression of c-Myc to 
promote cell proliferation (70). TNF-alpha can also increase MSC proliferation via the 
activation of downstream target proteins of the PI3K/Akt pathway, including NF-kB and 
cyclin D1 (72, 73). FGF-beta has been extensively studied to increase MSC proliferation and 
the activation of the PI3K/Akt pathway was shown to be important for the effect (74, 75). 
The pathway is also involved in EGF-increased MSC proliferation (76, 77). These factors 
may be studied in tissue engineering apparatus for their effects on the proliferation of MSCs 
and on the activity of the PI3K/Akt pathway. 
 
The role of the PI3K/Akt pathway in MSC proliferation has been demonstrated by activating 
the pathway by mutating the regulatory subunit of PI3K in MSCs. The subunit p85 
negatively regulates the catalytic subunit p110. The introduction of p85-/- into MSCs 
resulted in an increase in the level of pAkt (78). It was observed that over a span of 10 
continuous passages of cultured p85-/- MSCs, the cell proliferation rate was maintained, as 
indicated by the increased number of cells and the increased formation of colonies. Increased 
cell cycling was indicated by a lower number of cells in G1 and a greater number of cells in 
G2. There were consistent changes in the proteins regulating the cell cycle, including 
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increased levels of the cell cycle-promoting proteins cyclins D and E and reduced levels of 
the cell cycle blockers p16 and p19. 
 
 
2.4  The PI3K/Akt and MSC migration 
To be able to function properly, MSCs have to move to the appropriate place. MSCs are 
recruited into sites of injury by cytokines and chemokines so that these cells can help repair 
the injury (79). MSCs also move along vessels sprouting from endothelial cells to facilitate 
vessel formation and maintenance (80). Many studies have demonstrated that the migration 
ability of MSCs affects their efficacy (81, 82). Therefore, a greater understanding of the 
mechanisms involved in MSCs migration will facilitate the application of these cells in tissue 
engineering. 
 
Cell migration is closely related to changes in the cytoskeleton and to the formation of 
movement structures. The present theory of cell migration is summarized in several reviews 
(83, 84). In brief, actin plays a key role in cell movement (85), although several other 
structural proteins are involved in the cytoskeleton. During migration, cells become 
asymmetrical, forming front and back ends to direct cell movement. At the front, there are 
filopodia and lamellipodia. At the back, stress fibers, which are involved in cell adhesion, are 
formed or deformed to facilitate cell migration.  
 
The PI3K/Akt pathway is well known to affect cytoskeleton changes in many cells, 
particularly in cancer cells. p70(S6K), a downstream target of the PI3K/Akt pathway, can 
regulate cytoskeleton dynamics via actin filament cross-linking proteins (Fig 4). The 
overexpression of p70(S6K) in ovarian cancer cells promoted directional cell migration (86). 
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p70(S6K) stimulated the rapid activation of Rac-1 and CDC42 and their downstream effector, 
p21-activated kinase (PAK1) (86). Inhibition of p70(S6K) activity resulted in the decreased 
expression of these proteins and in actin cytoskeleton reorganization. In embryonic 
fibroblasts, Rac-1-null cells were defective in lamellipodia formation, cell spreading, cell-
fibronectin adhesion and focal contact formation when stimulated with platelet derived 
growth factor (PDGF) (87). The phosphorylation of PAK1 was reduced, and the 
reconstitution of active PAK1 counteracted this effect. Girdin, a newly found actin-binding 
protein, is also a substrate of Akt. The phosphorylation of girdin by Akt is important to 
girdin’s function in cell migration. Girdin is essential for the formation of stress fibers and 
lamellipodia in fibroblasts and endothelial cells (88, 89). The RNAi knockdown of girdin was 
found to disrupt the rearrangement of the actin cytoskeleton in vascular smooth muscle cells 
(VSMCs) (90). The girdin-related migration of endothelial cells is involved in angiogenesis 
(91). However, the role of girdin and its related signal pathways in MSC migration has not 
been studied. 
 
In MSCs, several PI3K/Akt stimulators have been shown to increase MSC migration. The 
role of SDF-1, one such stimulator, in MSC migration has been well studied (79). A study 
has shown that SDF-1 promoted MSC migration in a bone regeneration scaffold (92). SDF-1-
increased MSC migration was mediated by the activation of the PI3K/Akt pathway (39). 
Hypoxia conditioning has also been shown to increase MSC migration via the PI3K/Akt 
pathway, and this effect was abolished by the PI3K inhibitors wortmannin and LY294002 
(93, 94). However, the downstream target proteins of the PI3K/Akt pathway in MSC 
migration is not well understood and warrant further studies.  
 
 
 Page 11 of 35 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
Th
e 
ke
y 
re
gu
la
to
ry
 ro
le
s o
f t
he
 P
I3
K
/A
kt
 si
gn
al
lin
g 
pa
th
w
ay
 in
 th
e 
fu
nc
tio
na
lit
ie
s o
f m
es
en
ch
ym
al
 st
em
 c
el
ls 
an
d 
ap
pl
ic
at
io
ns
 in
 ti
ss
ue
 re
ge
ne
ra
tio
n 
(do
i: 1
0.1
08
9/t
en
.T
EB
.20
12
.06
72
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
12 
 
2.5  The PI3K/Akt pathway and MSC-induced angiogenesis 
Angiogenesis is necessary for the survival of new tissues formed by tissue engineering 
because blood vessels are required to supply nutrients and transport out wastes. MSCs can 
help vessels to grow and invade from neighboring tissues by promoting the formation of 
tubes by endothelial cells. MSCs can recruit pericytes and smooth muscle cells to promote 
the maturation of newly formed blood vessels (80). In addition, MSCs themselves can also 
differentiate into endothelial cell to increase vascularization (95).  
 
Several studies have demonstrated that the activation of the PI3K/Akt pathway increases the 
angiogenesis ability of MSCs. Several stimulators of the PI3K/Akt pathway, such as SDF-1 
and CoCl2, have been shown to increase angiogenesis. The overexpression of SDF-1 was also 
shown to increase angiogenesis (26). MiR-126-overexpressing MSCs increased the level of 
angiogenesis in an infarcted area in mice subjected to ligation of the coronary artery by 
increasing the levels of pAkt and pErk (96). The delivery of angiopoietin-1 with a Sendai 
virus-based vector to MSCs increased the pAkt levels and resulted in increased angiogenesis 
(97). Adrenomedullin, an activator of the PI3K/Akt pathway, was shown to increase 
angiogenesis when it was infused together with transplanted MSCs (25). The effect of MSCs 
on endothelial cells with respect to angiogenesis was also demonstrated using conditioned 
medium from MSC cultures. This medium increased the level of angiogenesis by increasing 
the level pAkt and the effect was inhibited by a PI3K/Akt inhibitor (98).  
 
2.6  The PI3K/Akt and cytokine production of MSCs 
MSCs can secrete many cytokines that regulate other cells and facilitate tissue repair; these 
cytokines include VEGF, FGF, monocyte chemoattractant protein-1 (MCP-1), HGF, insulin-
like growth factor-I (IGF-I), SDF-1 and thrombopoietin (99-101). The cytokines secreted by 
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MSCs are required for MSCs to exert their effects in infarcted heart tissue because the 
numbers of surviving MSCs and differentiated cells derived from MSCs are low(102). The 
secreted cytokines can promote the recruitment of local cells for injury repair. The role of 
cytokines secreted by MSCs as local regulators was further demonstrated by the ability of 
conditioned MSC medium to ameliorate myocardial infarction (103). Conditioned medium 
from MSC culture also increased wound healing indicated by recruitment of macrophages 
and endothelial cells (104). It has been shown that systemic delivery of BMSCs decreased 
neuropathy and this effect was reduced by anti-BDNF neutralising anti-bodies, indicating 
importance of MSC secreted factors. Secreted neuron growth factors such as NGF, BDNF 
and GDNF also facilitate the recovery from Alzheimer’s disease, Huntington’s disease, 
Parkinson’s disease, multiple sclerosis and Krabbe’s disease (105).  
 
 
Evidence has shown that the MSC’s ability to secrete cytokines is regulated by PI3K/Akt 
activity. SDF-1 has been shown to increase the secretion of cytokines by MSCs, and this 
effect is mediated by the PI3K/Akt pathway (39). The overexpression of Akt1 in MSCs 
increased the gene expression of VEGF, FGF-2, HGF and IGF-1 and thus increased the 
secretion of these cytokines (103). Akt1-induced cytokine secretion has been linked to the 
increased survival of infarcted myocardial cells. IL-6 and TNF-alpha can synergistically co-
stimulate MSCs to produce VEGF via the PI3K/Akt pathway (106). NF-kB, a downstream 
protein in the PI3K/Akt pathway, was also shown to play an important role in the TNF-alpha-
induced production of VEGF, FGF, HGF and IGF-1(107). 
 
These cytokines can also act on MSCs to affect their functionalities. For example, MSCs can 
express HGF receptor, c-Met (108, 109). HGF-expressing MSCs have a greater ability to 
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repair myocardial infarction, whereas HGF-null MSCs are unable to repair ischemic limbs 
(110, 111). This effect of HGF was demonstrated to be mediated by the PI3K/Akt pathway. 
HGF at a concentration of 20 ng/ml promoted osteogenic differentiation via the activation of 
c-Met,  Akt pathway and  the increased expression of cell cycle inhibitor p27 and osteogenic-
associated transcription factors Runx2 and osterix, whereas a high concentration of HGF (100 
ng/ml) promoted proliferation and suppressed osteogenic differentiation by activating Erk1/2 
pathway and inhibiting Akt pathway (112, 113). 
 
2.7 The PI3K/Akt pathway and MSC differentiation  
The PI3K/Akt pathway has been shown to be important in the differentiation of MSCs into 
various cell types. However, the roles of this pathway are complicated by controversial 
effects. For example, the levels of components of the PI3K/Akt pathway and its downstream 
proteins mTOR, FOXO1, p27(kip1) and p70S6K are increased during the differentiation of 
MSCs into adipocytes (114-116). The inhibition of this pathway with the PI3K-specific 
inhibitor LY294002 resulted in decreased adipogenesis, indicating that the PI3K/Akt pathway 
plays an important role in adipogenesis (114). The activation of the downstream protein 
mTOR is sufficient to promote adipogenesis, and this process is inhibited by rapamycin. It 
has been demonstrated that mTOR up-regulates PPAR-gamma and CEBP-alpha, two master 
adipogenic transcriptional factors (115) (Fig 5). Furthermore, the protein Lar (leukocyte 
common antigen related tyrosine phosphatase) negatively regulates the adipogenesis of MSCs 
by inhibiting the PI3K/Akt pathway (116).  
 
IGF-I has been expressed in MSCs to increase osteogenesis for bone repair, and the 
mechanism was shown involved the activation of IRS1-PI3K (106). Although IGF-1 can also 
activate mitogen-activated protein kinase (MAPK) pathway, several studies have shown that 
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inhibition of MAPKs increases rather than decreases the rate of osteogenesis (117-120), 
indicating the PI3K/Akt pathway plays the key role in IGF-1-induced osteogenesis. TNF-
alpha was shown to increase osteogenesis by activating NF-B in MSCs from human adipose 
tissue; this induction of osteogenesis by TNF-alpha was blocked by an NF-B inhibitor 
(121). The mechanically induced activation of Akt has also been shown to increase 
osteogenesis (122, 123). 
 
Several studies have yielded controversial results about the role of the PI3K/Akt pathway in 
adipogenesis and osteogenesis. Fitter et al showed that imatinib promoted adipogenesis by 
inhibiting PDGF-induced PI3K activity (124). Controversial results regarding the role of the 
PI3K/Akt pathway in osteogenesis have also been presented (125-131). Studies have shown 
that imatinib stimulates osteogenesis by inhibiting PDGFR/PI3K/Akt signaling in MSCs 
(132-134). The reason for this effect is not well understood. It is possible that PDGF induces 
adipogenesis via signaling pathways different from those involved in the stimulation by 
special adipogenic medium (1 µM dexamethasone, 0.2 mM indomethacin, 0.5 mM IBMX, 
0.01 mg/ml insulin and 10% FBS). It is now known that multiple signal pathways are 
involved in lineage determination. Canonical and non-canonical Wnts are involved in 
determining whether MSCs differentiate into osteocytes or adipocyte (135, 136). FGF was 
demonstrated to increase osteogenesis via FGFR1&2, which activate the PI3K/Akt and 
Erk1/2 pathways (137). The role of the interaction of multiple signal pathways in MSC 
differentiation has also been studied (138). However, no conclusive explanation has been 
revealed by the results.  
 
The importance of PI3K/Akt pathway in chondrogenesis has also been demonstrated. Insulin 
was shown to increase chondrogenesis via activation of PI3K/Akt pathway (139). IGF-1 also 
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promoted chondrogenesis via the same pathway and its downstream target protein NF-ĸB 
(140). Delta-like 1 protein, which inhibits Akt but not Erk1/2 and p38 MAPK reduced 
insulin-induced chondrogenic differentiation as demonstrated by a reduction of cartilage 
pellet formation and expression of genes involved in chondrogenesis such as aggrecan, 
collagen Type II and X (139). Addition of Delta-like 1 protein into chondrogenic medium 
produced a dose-dependent inhibition of chondrogenesis which was reversed by fibronectin. 
tan activator of the PI3K/Akt pathway (139). 
 
MSCs may also differentiate into other cells types such as neurons, cardiomyocytes, 
hepatocytes and pancreatic beta-cells (35). However, the role of PI3K/Akt pathway in the 
differentiation of these cells has not been studied well. Further exploration of the pathway 
may help to promote the potential use of MSCs in the regeneration of these cells. 
The roles of PI3K/Akt pathway in the functionalities of ASCs have also been studied but in a 
much less extent than that of BMSCs. It has been demonstrated that stimulation of the 
activity of Akt promoted the differentiation of ASCs into adipose tissue while inhibition of 
the pathway by Wartmannin reduced adipose tissue formation (141). Hypoxia condition has 
been shown to increase the survival ability, proliferation, angiogenesis, growth factor 
secreation and migration of ASCs via HIF-alpha/VEGF-A/PI3K/Akt pathway (142-146). 
Both neutralising antibodies against VEGF-A and inhibitor of PI3K may abolish the effect of 
hypoxia condition. These studies indicate that the pathway may also play a key role in ASCs 
in all aspects described above. More studies about the roles of the PI3K/Akt pathway in 
ASCs are warranted. 
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3. The effect of biomaterials on the activity of PI3K/Akt pathway in MSCs 
Effective tissue engineering such as bone regeneration required optimal interactions of three 
components including MSC cells, biomaterials used for scaffolds and bioactive molecules 
(147-151). Biomaterials are used not only for mechanical support but also stimulation of 
MSCs. At present many different kinds of biomaterials have been used to make scaffolds 
including polyners, calcium phosphate (CaP) and bioglass etc. Current studies in biomaterials 
attempt to increase their capability to stimulate MSCs to form new tissues. For the purpose, 
biomaterials with new properties have been made, surface structure of biomaterials has been 
modified and growth factors have been loaded to scaffolds. Biomaterials-increased MSC 
functionalities have been associated with the activation of the PI3K/Akt pathway as described 
in the following sections. 
 
3.1 Change of nature of biomaterials  
Novel biomaterials have been made so that they have increased capability to increase MSC 
functionalities. CaP such as β-tricalcium phosphate and  hydroxyapatite (HAP) possesses 
good mechanical properties, biocompatibility and osteoconductivity but it lacks 
biodegradability (12). Polymers are more popular for making scaffolds due to their property 
of biodegradation. However the disadvantage of polymers is that their osteoconductivity is 
very low. Woo et al developed a novel material using mixture of HAP and polymer PLLA 
called PLLA/HAP (152). In an in vitro culture system, this novel biomaterial has been shown 
to increase MSC cell survival as indicated by DNA content and decrease apoptosis detected 
by Tunel assay. The mechanism was demonstrated that PLLA/HAP could absorb more 
fibronectin and vitonectin which increased the activity of the PI3K/Akt as indicated by 
increased levels of pAkt and its downstream target bcl-2. This study provides a good example 
that manipulation of biomaterials can increase MSC functionalities via the activation of 
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PI3K/Akt pathway. At present, many biomaterials have been studied to increase MSC 
functionalities. However, the involvement of the PI3K/Akt is not extensively studied. It will 
be interesting to investigate how biomaterials affect MSC different functionalities through the 
PI3K/Akt and its downstream target proteins. Our studies have shown that cobalt chloride 
(CoCl2) can increase MSC proliferation and differentiation (49). It also increased MSC 
secretion of VEGF and thus increased vascularization in animal model (45). The PI3K/Akt 
pathway is likely to be involved in these effects. Several studies have shown that CoCl2 
induced hypoxia, which in turn activated the PI3K/Akt pathway to mediate CoCl2 biological 
effects (153-155). Further studies are warranted to characterize the direct effect of CoCl2 on 
the activity of the PI3K/Akt pathway and its downstream target proteins in MSCs.  
 
3.2 Modification of biomaterial surface 
Modification of the surface of biomaterials has also been used to increase MSC 
functionalites. Attachment of peptides to the surface of biomaterials has been shown to 
increase their stimulatory effect on MSCs (151). Several studies demonstrated that peptide 
Arg-Gly-Asp (RGD) attachment increased MSC survival, proliferation and differentiation 
(156-160). Zhang et al demonstrated that RGD attached poly (caprolactone)(PCL) increased 
MSC proliferation and this was mediated by the activation of the PI3K/Akt pathway (161). 
RGD activated an integrin which in turn increased Akt activity.  
 
3.3 Control of growth factor release in scaffolds 
Several growth factors such as FGF, TGF-beta and bone morphogenetic protein-2 (BMP-2) 
have been loaded on scaffold biomaterials to increase the efficacy of bone formation (15, 
162). BMP-2 has been incorporated into the biomaterial surface by several methods such as 
indirect adsorption, affinity binding or chemically conjugating (163, 164). The loading of 
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BMP-2 in scaffold biomaterials CaP, TCP and PCL increased bone formation (165-168). 
Release pattern of BMP-2 from scaffolds is recognised to be important and scaffold geometry 
has been used to achieve gradient release of BMP-2 (169-172). BMP-2 is known to increase 
osteogenesis via the activation of PI3K/Akt pathway (173). It will be interesting to study how 
BMP2 and other growth factors loaded in scaffolds and their release pattern affect the 
PI3K/Akt pathway in MSCs and thus alter MSC functionalities in tissue engineering 
apparatus. 
 
4. Conclusions and Future directions 
The bottleneck for MSCs in tissue engineering application is that their survival ability and 
functionality are very low (38). This could be overcome by activating the PI3K/Akt pathway 
in MSCs which plays key roles in the functionalities of MSCs including cell survival ability, 
cell proliferation, migration, angiogenesis, cytokine production and differentiation as 
discussed above. Therefore, activation of the pathway will increase the performance of MSC 
in tissue engineering. Indeed, several approaches have been applied to increase MSC 
functionalities including over-expression of genes, addition of growth factors and 
manipulation of biomaterials (43-48). Several studies showed that novel biomaterials, use of 
CoCl2, incorporation of peptides on the surface of biomaterials and loading growth factors in 
scaffolds can increase MSC functionalities (42, 49). Biomaterial-increased MSC 
functionalities have been associated with the activation of the PI3K/Akt pathway.  
 
In future, the ability of a biomaterial to activate PI3K/Akt in MSCs in vitro system could be 
used for selection criteria for the use in tissue engineering. Activation of the PI3K/Akt 
pathway could indicate the effect of biomaterials on MSC functinalities. It will be interesting 
to study how biomaterials affect the downstream target proteins of the PI3K/Akt pathway in 
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associated with different functionalities of MSCs. How loaded growth factors in scaffolds 
activate the PI3K/Akt and its downstream targets in MSCs could be studied. MSCs have been 
engineered genetically to over-express regulatory genes to increase their functionalities in 
cellular therapy. It is interesting to investigate whether biomaterials have synergistic effect 
with these MSCs. Combinational applications of genetic engineered MSCs, growth factors 
and bioactive biomaterials could be an effective approach for successful tissue regeneration. 
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Figure legends 
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Fig 1 The PI3K/Akt pathway in MSCs  
The activity of the PI3K/Akt pathway in MSCs can be stimulated by growth factors or 
hypoxia. Activated Akt promotes MSC proliferation, angiogenesis, survival and migration 
via downstream target proteins such as mTOR, VEGF, Bcl-2 and Rac-1. 
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Fig 2 PI3K and the survival of MSCs 
In MSCs, the activity of the PI3K/Akt pathway is stimulated by SDF-1 and LPS and by the 
overexpression of periostin. Activated Akt can increase MSC survival by blocking bax, 
which is a pro-apoptotic protein, and by increasing Bcl-2, which can reduce the level of 
apoptosis. 
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Fig 3 PI3K and the proliferation of MSCs 
Phosphorylated Akt can block the p16 and p19 proteins and promote an increase in cell 
cycling of MSCs via cyclin D and E. Phosphorylated Akt also prevents GSK-3beta from 
forming a complex with beta-catenin, resulting in the accumulation of beta-catenin. 
Accumulated beta-catenin can increase the expression of myc, which is known to increase 
cell proliferation. Akt also increases proliferation via the NF-kB pathway. 
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Fig 4 MSC migration promoted by the PI3K/Akt pathway 
PI3K can activate Akt, which in turn increases the expression of RhoA, thus changing the 
cytoskeleton. Akt also phosphorylates p70S6K, which increases Rac-1 and CDC42 
expression, leading to PAK1 activation and cytoskeleton changes. PI3K also directly acts on 
Rac-1. 
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Fig 5 PI3K and adipogenesis 
The PI3K/Akt pathway can regulate adipogenesis via mTOR, which can increase the levels of 
PPAR-gamma and CEBP-alpha. The PI3K-specific inhibitor LY294002 and the mTOR 
inhibitor rapamycin decrease the level of adipogenesis. 
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